Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nicotine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CVSI-007 contains nicotine and cannabidiol which supports the cessation of smokeless tobacco use and addiction, if approved it'll be the first and only treatment for smokeless tobacco addiction.
Product Name : CVSI-007
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 23, 2023
Lead Product(s) : Nicotine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CV Sciences and University of California Publish Study of Cannabidiol Efficacy
Details : In this study, rats dependent on nicotine and experiencing withdrawals were treated with CBD. Treatment prevented the animals from exhibiting withdrawal symptoms – including increased pain sensitivity and weight gain – during short- and long-term nic...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable